Protagonist Therapeutics, Inc. $PTGX Shares Purchased by Jupiter Asset Management Ltd.

Jupiter Asset Management Ltd. grew its stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) by 141.4% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 405,644 shares of the company’s stock after purchasing an additional 237,581 shares during the period. Jupiter Asset Management Ltd. owned approximately 0.65% of Protagonist Therapeutics worth $22,420,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also modified their holdings of the business. Envestnet Asset Management Inc. lifted its holdings in Protagonist Therapeutics by 85.7% during the 1st quarter. Envestnet Asset Management Inc. now owns 16,679 shares of the company’s stock worth $807,000 after buying an additional 7,698 shares in the last quarter. Xponance Inc. acquired a new stake in Protagonist Therapeutics during the 1st quarter worth approximately $216,000. New York State Common Retirement Fund grew its position in Protagonist Therapeutics by 9.5% in the 1st quarter. New York State Common Retirement Fund now owns 19,582 shares of the company’s stock valued at $947,000 after buying an additional 1,700 shares during the last quarter. Jennison Associates LLC purchased a new stake in Protagonist Therapeutics in the 1st quarter valued at approximately $886,000. Finally, Y Intercept Hong Kong Ltd acquired a new position in shares of Protagonist Therapeutics during the 1st quarter worth $975,000. 98.63% of the stock is currently owned by hedge funds and other institutional investors.

Protagonist Therapeutics Trading Down 0.8%

Shares of NASDAQ PTGX opened at $84.85 on Thursday. The company has a market capitalization of $5.30 billion, a price-to-earnings ratio of 136.86 and a beta of 2.22. Protagonist Therapeutics, Inc. has a twelve month low of $33.31 and a twelve month high of $93.25. The firm has a 50-day moving average of $70.10 and a two-hundred day moving average of $58.38.

Protagonist Therapeutics (NASDAQ:PTGX) last announced its earnings results on Thursday, November 6th. The company reported ($0.62) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.59) by ($0.03). The firm had revenue of $4.71 million for the quarter, compared to analyst estimates of $5.41 million. Protagonist Therapeutics had a net margin of 21.94% and a return on equity of 6.86%. As a group, research analysts predict that Protagonist Therapeutics, Inc. will post 2.43 earnings per share for the current year.

Insider Transactions at Protagonist Therapeutics

In other Protagonist Therapeutics news, Director William D. Waddill sold 12,000 shares of Protagonist Therapeutics stock in a transaction that occurred on Friday, October 10th. The stock was sold at an average price of $81.62, for a total value of $979,440.00. Following the transaction, the director directly owned 5,130 shares of the company’s stock, valued at $418,710.60. The trade was a 70.05% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. In the last quarter, insiders have sold 20,000 shares of company stock valued at $1,473,440. Company insiders own 4.90% of the company’s stock.

Wall Street Analysts Forecast Growth

PTGX has been the topic of a number of recent research reports. Citigroup upped their target price on Protagonist Therapeutics from $96.00 to $98.00 and gave the company a “buy” rating in a research note on Monday. HC Wainwright reissued a “buy” rating and set a $80.00 price target on shares of Protagonist Therapeutics in a research report on Wednesday, October 8th. JPMorgan Chase & Co. increased their price objective on shares of Protagonist Therapeutics from $68.00 to $81.00 and gave the stock an “overweight” rating in a research report on Friday, November 7th. JMP Securities lifted their price objective on shares of Protagonist Therapeutics from $67.00 to $69.00 and gave the company a “market outperform” rating in a research note on Thursday, August 7th. Finally, Citizens Jmp boosted their price target on Protagonist Therapeutics from $69.00 to $102.00 and gave the stock a “market outperform” rating in a research note on Friday, November 7th. One analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $82.23.

Protagonist Therapeutics Company Profile

Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.